Skip to content

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

Home
- Home
About BR&R
Biosimilar Approval Status
BR&R Product Profiles
- Abrilada
- Amjevita
- Avasola
- Byooviz
- Cyltezo
- Erelzi
- Eticovo
- Fulphila
- Fylnetra
- Hadlima
- Herzuma
- Hulio
- Hyrimoz
- Inflectra
- Kanjinti
- Mvasi
- Nivestym
- Nyvepria
- Ogivri
- Ontruzant
- Releuko
- Renflexis
- Retacrit
- Riabni
- Ruxience
- Semglee
- Trazimera
- Truxima
- Udenyca
- Yusimry
- Zarxio
- Ziextenzo
- Zirabev
Contact Us
The 2023 Biosimilars Market Report

$0.00 0 items

video_2_edelbaum-mp4

October 8, 2018October 8, 2018

Published by

View all posts by

Published October 8, 2018October 8, 2018

Post navigation

Previous Post video_2_edelbaum-mp4

Leave a Reply Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

SM Health Comm

Search for:

Recent Posts

Celltrion Earns FDA Nod for Bevacizumab Biosimilar September 29, 2022
FDA’s BsUFA III Features September 28, 2022
The Inflation Reduction Act: Reducing Drug Prices and Maybe Future Biosimilar Development September 22, 2022
Can Biosimilar Development Costs Be “Genericized”? September 16, 2022
FDA Approves Fresenius Kabi’s Pegfilgrastim Biosimilar Stimufend September 9, 2022
Alvotech’s Adalimumab BLA Tripped Up by FDA September 7, 2022
Samsung Bioepis and Organon Score Citrate-Free, High-Concentration Dose Approval August 18, 2022
Tocilizumab Biosimilars Approaching: Developments on Three Fronts August 18, 2022
Appeals Court Says “So What?” to Patent Thickets August 5, 2022
Coherus Scores Approval of Cimerli® as Interchangeable Ranibizumab Biosimilar August 4, 2022

Recent Comments

	FDA's BsUFA III… on Sandoz Submits 351(k) Applicat…
	Stanton Mehr on Appeals Court Says “So What?”…
	Vincent Capuano on Appeals Court Says “So What?”…
	Can Biosimilar Devel… on It Will Be Difficult to Move A…
	Samsung Bioepis and… on Preliminary Phase 3 Study Data…

Archives

Archives

Meta

Log in
Entries feed
Comments feed
WordPress.org

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Email Address

Top Posts & Pages

The Evolution of the Biosimilars Market
Amjevita
Abrilada
Hyrimoz
Amgen, Pfizer Now Seeking Adalimumab Interchangeability, but…
Biosimilar Approval Status
Adalimumab Interchangeability Competition Coming into Focus
Cyltezo
Celltrion Earns FDA Nod for Bevacizumab Biosimilar
Pfizer Launches Ruxience, Announces Pricing for Upcoming Trazimera

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

Twitter
LinkedIn

Home
About BR&R
Biosimilar Approval Status
Contact Us
Terms and Conditions

Copyright

Copyright 2013-2022 by SM Health Communications. All Rights Reserved

Powered by WordPress.com.